Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. regarding potential securities fraud or unlawful business practices [1] - Fortrea's stock has experienced significant declines following downgrades from Jefferies and Baird due to concerns over its business model and abrupt cancellations of scheduled conferences [2][3] Group 1: Company Performance - On September 25, 2024, Jefferies downgraded Fortrea, leading to a stock price drop of $2.73 per share, or 12.29%, closing at $19.48 per share [2] - On December 6, 2024, Baird downgraded Fortrea to neutral from outperform, resulting in a stock price decline of $1.90 per share, or 8.06%, closing at $21.67 per share [3] Group 2: Legal Investigation - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, and is currently investigating Fortrea for potential securities fraud [1][4]

Company Overview - Fortrea (Nasdaq: FTRE) is a leading global contract research organization (CRO) that provides clinical development solutions to the life sciences industry [3] - The company partners with biopharmaceutical, biotechnology, medical device, and diagnostic companies to accelerate healthcare innovation and deliver life-changing therapies to patients [3] - Fortrea offers services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over 30 years of experience across more than 20 therapeutic areas [3] Financial Results Announcement - Fortrea will release its fourth quarter and full year 2024 financial results on March 3, 2025, before the market opens [1] - A conference call will be held at 9:00 am ET on the same day to review the financial results and conduct a Q&A session [1][2] Participation Details - Participants can register for the earnings call online at the Fortrea Investor Relations website and are advised to join at least 10 minutes early to avoid delays [2] - A replay of the conference call will be available shortly after the event on the Fortrea Investor Relations website [2]

Group 1 - The article highlights that while investors are focused on tech stocks in 2024, the healthcare sector is also experiencing significant innovation [1] - There is a suggestion that the healthcare industry may offer comparable investment opportunities as the tech sector, despite being overlooked [1] Group 2 - The author has a beneficial long position in the shares of FRTE, indicating a personal investment interest in the stock [1] - The article emphasizes the author's experience and success in the stock market, with an average stock return of over 31% from previous articles [2]

DURHAM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Citi Global Healthcare Conference on Wednesday, December 4, 2024 at 1:45 pm ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after th ...

Core Viewpoint - Fortrea, a leading global contract research organization, is set to present at the Evercore HealthCONx Conference on December 5, 2024, highlighting its role in clinical development solutions for the life sciences industry [1]. Company Overview - Fortrea (Nasdaq: FTRE) specializes in providing clinical development solutions to the life sciences sector, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to enhance healthcare innovation [3]. - The company offers a range of services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over 30 years of experience across more than 20 therapeutic areas [3]. - Fortrea operates in approximately 100 countries, emphasizing a strong investigator site network and a commitment to scientific rigor and exceptional insights [3].

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -14.81%. A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced a loss of $0.03, delivering a surprise of -142.86%.Over the last four quarters, the c ...

For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 millionGAAP net loss of $(18.5) millionAdjusted EBITDA of $64.2 millionGAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectivelyBook-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial r ...

Fortrea Holdings Inc. (FTRE) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released o ...

, Oct. 18, 2024 (GLOBE NEWSWIRE) -- (CRO) Fortrea (Nasdaq: FTRE) Fortrea (Fortrea for Better) Fortrea.com Fortrea (ESG) | --- | --- | --- | |---------|-------|-------| | | | | | Fortrea | | | | Fortrea | | | | Fortrea | | | | Fortrea | | | "Fortrea " ESG Sandy Kennedy Fortrea 100 300 "" (ERG) Fortrea 4,000 Fortrea (CSR) ESG Fortrea Tom Pike 2,500 CEO Action for Diversity & Inclusion™ () (DEI) Fortrea EcoVadis CDP—— Fortrea 2026 ""Tom Pike "" Fortrea Fortrea (Nasdaq: FTRE) Fortrea I IV Fortrea 20 100 / Fortr ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ: FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE. Investigation Details On September 25, 2024, Jefferies downgraded Fortrea, citing perceived weaknesses in the Comp ...